Ropeginterferon Alfa-2b Demonstrates Long-Term QOL Improvements in Polycythemia Vera
June 13th 2022Treatment with ropeginterferon alfa-2b-njft induced low symptom burden and low phlebotomy requirement compared with best available treatment in patients with polycythemia vera, according to long-term data from the phase 3 PROUD-PV and CONTINUATION-PV trials.
Read More
CAR T-Cell Therapy ARI0002H Elicits Encouraging Responses in Relapsed/Refractory Multiple Myeloma
June 11th 2022ARI0002H, a BCMA-directed CAR T-cell therapy, achieved promising response rates in patients with relapsed/refractory multiple myeloma, according to findings from a phase 1/2 trial.
Read More
NPM1 Mutations, MRD Responses Linked to Long-Term Survival Benefits With Azacitidine in AML
June 10th 2022Oral azacitidine was associated with improved long-term survival in patients with acute myeloid leukemia who harbored NPM1 mutations, had intermediate-risk cytogenetics at diagnosis, had a longer treatment duration, or a minimal residual disease response during treatment.
Read More
Frontline BTK Inhibitors Improve OS in Real-World Patients with MCL
June 2nd 2022The use of BTK inhibitors as a frontline treatment improved overall survival vs their deployment in subsequent lines of therapy in patients with mantle cell lymphoma, according to a real-world study (IRB-300004501) published in Blood Advances.
Read More
Fixed-Duration Ibrutinib/Venetoclax Significantly Prolongs PFS Over SOC in CLL and Comorbidities
June 2nd 2022The fixed-duration combination of ibrutinib and venetoclax produced deep responses and improved progression-free survival vs chlorambucil plus obinutuzumab when used in previously untreated patients with chronic lymphocytic leukemia who were older and/or who had comorbidities, according to findings from the phase 3 GLOW trial.
Read More
Zanubrutinib Approved in Uruguay for MCL, MZL, and Waldenström Macroglobulinemia
May 27th 2022The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.
Read More
Nivolumab Plus Axitinib Generates Promising Responses in Untreated Advanced RCC
May 24th 2022The combination of nivolumab and axitinib achieved meaningful responses in treatment-naïve advanced renal cell carcinoma, according to results from a phase 1/2 trial (NCT03172754) presented at the 2022 Genitourinary Cancers Symposium.
Read More
European Approval Sought for Adagrasib in Previously Treated KRAS G12C–Mutated NSCLC
May 20th 2022A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of adagrasib for therapeutic use in previously treated patients with non–small cell lung cancer harboring a KRAS G12C mutation.
Read More
Navicixizumab/Paclitaxel Combo Demonstrates Early Promise in Platinum-Resistant Ovarian Cancer
May 13th 2022The addition of navicixizumab to paclitaxel produced encouraging responses with manageable toxicity in patients with platinum-resistant ovarian cancer irrespective of prior treatment with bevacizumab.
Read More
VB10.16 Plus Atezolizumab Elicits Responses in HPV16-Positive Cervical Cancer
May 10th 2022The first-in-class, off-the-shelf therapeutic cancer vaccine VB10.16 in combination with atezolizumab generated positive responses in heavily pretreated patients with HPV16-positive advanced cervical cancer.
Read More
The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.
Read More
Neoadjuvant and Adjuvant Therapy Elicit Similar Efficacy in Early-Stage HER2+ Breast Cancer
May 6th 2022Neoadjuvant therapy generated similar benefits to adjuvant therapy in patients with early-stage, HER2-positive breast cancer treated in China, suggesting that neoadjuvant therapy should be used in this patient population.
Read More
The addition of ribociclib to fulvestrant continued to significantly prolong overall survival, delayed time to second disease progression, and improved chemotherapy-free survival vs placebo plus fulvestrant in the first-line treatment of patients with advanced hormone receptor–positive, HER2-negative breast cancer.
Read More
CG0070 Plus Nivolumab Under Investigation in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
May 4th 2022The safety and efficacy of the combination of the oncolytic immunotherapy CG0070 and nivolumab is under exploration as a potential therapeutic option in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, as part of the phase 1b CORE-002 trial.
Read More
Pembrolizumab With or Without Chemo Has Increased Efficacy With Increasing PD-L1 Expression in HNSCC
May 4th 2022Pembrolizumab with or without chemotherapy resulted in a numerically longer overall survival benefit vs cetuximab plus chemotherapy in patients with head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) between 1 and 19, but did not improve survival in the subset with a PD-L1 CPS of less than 1.
Read More
Tucatinib Plus T-DM1 Represents Another Potential Therapy in High-Risk HER2-Positive Breast Cancer
May 3rd 2022Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.
Read More